Danske Bank A/S Revolution Medicines, Inc. Transaction History

Danske Bank A/S

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 19, 2025	BUY	$34.7 - $46.7 $72,870 - $98,070	2,100 New	2,100 $98,000
Q2 2025 Dec 18, 2025	BUY	$31.13 - $41.98 $59,147 - $79,762	1,900 Added 950.0%	2,100 $77,000
Q1 2025 Dec 18, 2025	SELL	$35.36 - $44.42 $67,184 - $84,398	-1,900 Reduced 90.48%	200 $7,000

357

195M

2.66M

945K

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $5.94B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Danske Bank A/S, based on Form 13F filings with the SEC.

Stay updated on Danske Bank A/S with notifications on news.